Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized IPO at $20.00 per share for 33.5 million shares, expected to raise $670 million in gross proceeds. The company will also conduct a concurrent private placement with Regeneron Pharmaceuticals for 4.17 million shares at $18.00 per share, raising approximately $75 million. Trading on Nasdaq under ticker 'PBLS' is expected to begin June 10, 2026.